Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NC100150

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Five types of superparamagnetic iron oxide (SPIO), i.e. Ferumoxides (Feridex(®) IV, Berlex Laboratories), Ferucarbotran (Resovist… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The purpose of this study was to determine the cellular distribution and degradation in rat liver following intravenous injection… Expand
  • figure 1
  • figure 2
  • figure 5
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE To investigate the physiological origins responsible for the varying blood oxygenation level dependent (BOLD) magnetic… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE To define the diagnostic potential of magnetic resonance (MR) imaging enhanced with ultrasmall superparamagnetic iron… Expand
Is this relevant?
2000
2000
A preparation of monocrystalline iron oxide nanoparticles with an oxidized starch coating, currently in clinical trials (NC100150… Expand
Is this relevant?
2000
2000
The influence of increasing doses of NC100150 Injection (Clariscantrade mark) and echo times on visualization of pulmonary… Expand
Is this relevant?
1999
1999
In this Phase I clinical study, a novel ultrasmall superparamagnetic iron oxide contrast agent, NC100150 Injection (Nycomed… Expand
Is this relevant?
1999
1999
Recent developments of novel magnetic resonance intravascular contrast agents with low T1 in blood and a long intravascular half… Expand
  • figure 1
  • figure 2
  • table I
  • table 2
Is this relevant?
1999
1999
A new ultrasmall superparamagnetic iron oxide (Clariscan; NC100150 Injection) was studied in domestic farm pigs. The T1 effects… Expand
Is this relevant?
1999
1999
This is the first study of the intravascular iron oxide particle contrast agent, NC100150 Injection (Nycomed Imaging AS, Oslo… Expand
  • table I
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?